Evidence map›Paper›PMID 31379831›Full record

ArticleFrontiers in immunology2019

Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus.

Rustem I Litvinov, Rosa M Nabiullina, Laily D Zubairova, Mileusha A Shakurova, Izabella A Andrianova, John W Weisel

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Fibrinogen and Fibrin.Sub-cellular biochemistry · 2021
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Rustem I LitvinovDepartment of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Rosa M NabiullinaDepartments of Biochemistry and General Pathology, Kazan State Medical University, Kazan, Russia.
Laily D ZubairovaDepartments of Biochemistry and General Pathology, Kazan State Medical University, Kazan, Russia.
Mileusha A ShakurovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
Izabella A AndrianovaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.
John W WeiselDepartment of Cell and Developmental Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Kazan Federal University · RUKazan State Medical University · RUUniversity of Pennsylvania · US

Funding

Multiscale modeling and empirical study of a mechanism limiting blood clot growthU01HL116330 · NHLBI · UNIVERSITY OF NOTRE DAME · PI ALBER, MARK · 2014 to 2018
$3.5M
Structural origin of fibrin clot mechanical propertiesR01HL090774 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI WEISEL, JOHN W · 2009 to 2012
$1.6M
NHLBI NIH HHS R01 HL090774NHLBI NIH HHS U01 HL116330
6 · The paper itself

Abstract

Among complications of systemic lupus erythematosus (SLE), thrombotic events are relatively common and contribute significantly to the morbidity and mortality rates. An increased risk of thrombosis in various diseases has been shown to be associated with the lytic stability and mechanical stiffness of the fibrin clot determined by its structure. Here we studied alterations of the fibrin clot properties in relation to disease severity in SLE patients. Plasma clots from 28 SLE patients were characterized by the kinetics of formation and fibrinolytic dissolution (using dynamic turbidimetry), the network and fiber ultrastructure (scanning electron microscopy), viscoelasticity (shear rheometry), and the rate and degree of crosslinking (Western blotting) correlated with the disease activity, blood composition, and compared to clotting of pooled normal human plasma. Clots made from plasma of SLE patients were lysed faster with exogenous t-PA than control clots from normal plasma without a significant difference between those from active (SLEDAI>4) and inactive (SLEDAI<4) SLE patients. Clots from the blood of patients with active SLE were characterized by significantly slower onset, but faster rate of fibrin polymerization and a higher optical density due to thicker fibers compared to those from inactive SLE and control pooled normal plasma. The rheological parameters of the clots (storage and loss moduli) were significantly increased in the active SLE patients along with enhanced fibrin crosslinking and hyperfibrinogenemia. The structural and rheological alterations displayed a strong positive correlation with high fibrinogen levels and other laboratory markers of immune inflammation. In conclusion, changes in the blood composition associated with active systemic inflammation in SLE cause significant alterations in the lytic resistance of fibrin clots associated with changes in polymerization kinetics, viscoelastic properties, and structure. The formation of more rigid prothrombotic fibrin clots in the plasma of SLE patients is likely due to the inflammatory hyperfibrinogenemia and greater extent of crosslinking. However, the higher susceptibility of the SLE clots to fibrinolysis may be a protective and/or compensatory mechanism that reduces the risk of thrombotic complications and improves patient outcomes.

Indexed as

AdultFemaleFibrinFibrinogenFibrinolysisHumansLupus Erythematosus, SystemicMaleMicroscopy, Electron, ScanningThrombosisFibrinFibrinogenfibrinogenfibrinolysisfibrin structurefibrin viscoelasticitysystemic lupus erythematosus

Identifiers

PMID31379831
PMCPMC6646676
OpenAlexW2957207615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.